Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

COX-2 inhibitor ECP-1014

An orally bioavailable inhibitor of the enzyme cyclooxygenase-2 (COX-2), with potential analgesic, anti-inflammatory and antineoplastic activities. Upon oral administration, COX-2 inhibitor ECP-1014 inhibits COX-2, thereby inhibiting the conversion of arachidonic acid to prostaglandins, including prostaglandin E2 (PGE2). This may reduce pain and inflammation. The COX-2/PGE 2 pathway may also play an important role in tumor proliferation, angiogenesis, metastasis and immune suppression in the tumor microenvironment (TME). COX-2 is overexpressed in certain tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	cyclooxygenase-2 inhibitor ECP-1014
Code name:	ECP 1014 ECP-1014 ECP1014 GIBH-1014

COX-2 inhibitor ECP-1014

Search NCI's Drug Dictionary